Investor Day Slides

WORLD CLASS RETINA EXPERTISE AXPAXLI Has Demonstrated Proof-of-Concept in Three Phase 1 trials wAMD Trials Demonstrated Monotherapy Proof-ofConcept and Potential Best–in–class Durability Phase 1 Australia Trial1: Monotherapy Activity Month 9 CSFT: 244µm BCVA: 81 letters (20/25) Month 6 CSFT: 239µm BCVA: 80 letters (20/25) Month 2 CSFT: 236µm BCVA: 74 letters (20/30) Baseline CSFT: 484µm BCVA: 56 letters (20/80) Treatment naïve & experienced patients Treatment naïve & experienced patients Patients received n ...